Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.06.019
Abstract: Introduction: EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR‐activating alterations relatively insensitive to first‐ and second‐generation EGFR tyrosine kinase inhibitors (TKIs). However, recent early clinical data suggests these patients may benefit from… read more here.
Keywords: generation egfr; egfr; comprehensive genomic; egfr exon ... See more keywords
ERBB2 exon 20 insertions are rare in Brazilian non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14605
Abstract: ERBB2 exon 20 insertions may impact the clinical management of lung cancer patients. However, the frequency of ERBB2 exon 20 insertions in lung cancer patients in Brazil is scarce. Here, we analyzed 722 Brazilian non‐small… read more here.
Keywords: lung cancer; erbb2 exon; cancer; exon insertions ... See more keywords
Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.9030
Abstract: 9030Background: EGFR exon 20 insertions (Ex20Ins), the 3rd most common EGFR activating mutation, are generally unresponsive to 1st and 2nd generation EGFR-TKIs. Development of EGFR-TKIs that effectively target NSCLC with Ex20Ins mutations represents a major… read more here.
Keywords: egfr; egfr exon; harboring egfr; exon insertions ... See more keywords
Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
Sign Up to like & getrecommendations! Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines9121938
Abstract: The majority of lung cancers are non-small-cell lung cancer (NSCLC) having a low survival rate. Recent studies have indicated the involvement of epidermal growth factor receptor (EGFR) oncogene mutations like EGFR exon 20 insertions (EGFRex20ins)… read more here.
Keywords: patent; egfr exon; mobocertinib; egfrex20ins mutation ... See more keywords